MUMBAI, India, Aug. 1 -- Intellectual Property India has published a patent application (202517066465 A) filed by Eli Lilly And Company, Indianapolis, on July 11, for 'therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same.'
Inventor(s) include Garg, Ashish; Kaur, Amritpreet; Krege, John Henry; Ma, Xiaosu; Ni, Wei; and Haw, Helle Linnebjerg.
The application for the patent was published on Aug. 1, under issue no. 31/2025.
According to the abstract released by the Intellectual Property India: "Pharmaceutical compositions are disclosed that include a double-stranded RNAi agent that modulates LPA expression or its pharmaceutically acceptable salt thereof in water. Doses and dosing regimens for such RNAi agents also are disclosed that include administering doses from about 4 mg to about 608 mg at a frequency of monthly to yearly."
The patent application was internationally filed on Jan. 12, 2024, under International application No.PCT/US2024/011378.
Disclaimer: Curated by HT Syndication.
